Cost-effectiveness analysis of epidural morphine/ropivacaine treatment in patients with cancer pain.
Liliana Batista VieiraCarlos Marcelo de BarrosPrice Udo PriceMárcia Helena Miranda Cardoso PodestáSamea Araújo PereiraAlexander ItriaLarissa Helena Lobo TorresLeonardo Régis Leira PereiraPublished in: Pain practice : the official journal of World Institute of Pain (2023)
To present a better cost-effectiveness ratio, a reduction in the cost of the new epidural technology or an increase in the value of the existing oral intervention would be required. However, the latter is not feasible and unlikely to occur. A value judgement to decide whether the incremental benefit associated with the use of the new intervention is worth the extra cost will have to be made by the healthcare provider. Interventions that can relieve cancer pain symptoms should be investigated continuously, in search of evidence to support clinical practice and promote better quality of life for patients.
Keyphrases
- chronic pain
- healthcare
- randomized controlled trial
- spinal cord
- end stage renal disease
- clinical practice
- pain management
- neuropathic pain
- ejection fraction
- chronic kidney disease
- newly diagnosed
- primary care
- physical activity
- prognostic factors
- papillary thyroid
- squamous cell carcinoma
- squamous cell
- social media
- depressive symptoms
- young adults
- smoking cessation
- combination therapy
- replacement therapy